Neuropharmacological Mechanisms of Psychedelics: Advancing Treatment Strategies for Mental Health Disorder

Year : 2025 | Volume : 15 | Issue : 03 | Page : 67 79
    By

    Vaishali G. Mundhe,

  • Priya S. Daingade,

  • Pranjali D. Ugale,

  • Kiran P. Bhosale,

  • Tushar T. Shelke,

  • Poonam Ingle,

  • Sakshi Mehetre,

  • Pratiksha Pawar,

  1. Assistant Professor, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  2. Assistant Professor, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  3. Assistant Professor, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  4. Assistant Professor, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  5. Principal, Department of Pharmacology, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  6. Student, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  7. Student, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India
  8. Student, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Baif Rd, Wagholi, Pune, Maharashtra, India

Abstract

The resurgence of interest in the therapeutic potential of psychedelic drugs has caused a major upheaval in the field of psychiatry in recent years. This review’s main goal is to thoroughly examine the possible benefits of psychedelic drugs in the field of psychiatry, with a focus on how they might be used as psychotherapy aids. Given their widespread use in therapeutic settings, clinical trials involving MDMA, psilocybin, ketamine, and LSD were of special interest. According to a study, these psychedelic drugs could be used in conjunction with different types of therapy to safely and effectively treat major depressive disorder (MMD), obsessive compulsive disorder (OCD), PTSD and comorbid conditions, depression and anxiety in life-threatening diseases, and various substance use disorders. In conclusion, this study shows that psychedelic drugs have therapeutic promise in psychotherapy and can be used safely and effectively to treat a variety of mental health conditions.

Keywords: Psychedelics, Hallucinogenic Drugs, MDMA, Psilocybin, Ketamine.

[This article belongs to Research and Reviews: A Journal of Pharmacology ]

How to cite this article:
Vaishali G. Mundhe, Priya S. Daingade, Pranjali D. Ugale, Kiran P. Bhosale, Tushar T. Shelke, Poonam Ingle, Sakshi Mehetre, Pratiksha Pawar. Neuropharmacological Mechanisms of Psychedelics: Advancing Treatment Strategies for Mental Health Disorder. Research and Reviews: A Journal of Pharmacology. 2025; 15(03):67-79.
How to cite this URL:
Vaishali G. Mundhe, Priya S. Daingade, Pranjali D. Ugale, Kiran P. Bhosale, Tushar T. Shelke, Poonam Ingle, Sakshi Mehetre, Pratiksha Pawar. Neuropharmacological Mechanisms of Psychedelics: Advancing Treatment Strategies for Mental Health Disorder. Research and Reviews: A Journal of Pharmacology. 2025; 15(03):67-79. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=229587


References

1. De Gregorio, D., Aguilar-Valles, A., Preller, K.H., Heifets, B.D., Hibicke, M., Mitchell, J. and Gobbi, G., 2021. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience, 41(5), pp.891-900.
2. Gill, H., Gill, B., Chen-Li, D., El-Halabi, S., Rodrigues, N.B., Cha, D.S., Lipsitz, O., Lee, Y., Rosenblat, J.D., Majeed, A. and Mansur, R.B., 2020. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Review of Neurotherapeutics, 20(12), pp.1263-1273.
3. Elharake, J.A., Akbar, F., Malik, A.A., Gilliam, W. and Omer, S.B., 2023. Mental health impact of COVID-19 among children and college students: A systematic review. Child Psychiatry & Human Development, 54(3), pp.913-925.
4. Wheeler, S.W. and Dyer, N.L., 2020. A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice, 7(3), p.279.
5. Torres, A., Palomin, A., Morales, F., Sevilla-Matos, M., Colunga-Rodríguez, C., Ángel-González, M., Sarabia-López, L.E., Dávalos-Picazo, G., Delgado-García, D., Duclos-Bastías, D. and Vazquez-Colunga, J.C., 2023. A cross-sectional study of the mental health symptoms of Latin American, US Hispanic, and Spanish college students amid the COVID-19 pandemic. International Journal of Mental Health and Addiction, 21(6), pp.3865-3884.
6. Valencia, P.D., Torres-Quispe, M.A., Sánchez-Cayo, S., Reyes-Aguilar, R.F. and Acevedo-Cahuana, A.G., 2022. Factors associated with depressive symptomatology during the COVID-19 pandemic in Mexico: A 2021 national survey. Journal of affective disorders, 317, pp.212-220.
7. Cuijpers, P., Van Straten, A., Andersson, G. and Van Oppen, P., 2008. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. Journal of consulting and clinical psychology, 76(6), p.909.
8. Lisanby, S. H., 2007. Electroconvulsive Therapy for Depression. New England Journal of Medicine, 357(19), 1939–1945.
9. Gagen, B., 2022. The Use of Hallucinogens in the Treatment of Mental Health Disorders.
10. Taylor, S., Thordarson, D.S., Maxfield, L., Fedoroff, I.C., Lovell, K. and Ogrodniczuk, J., 2003. Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. Journal of consulting and clinical psychology, 71(2), p.330.
11. Sumner, J., 2023. Anxiety Screening in Adults: Improving Outcomes in a Clinical Setting (Doctoral dissertation, Shepherd University).
12. Martin, J.L.R., Sainz-Pardo, M., Furukawa, T.A., Martin-Sanchez, E., Seoane, T. and Galan, C., 2007. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology, 21(7), pp.774-782.
13. U.S. Department of Health and Human Services. Obsessive-Compulsive Disorder. National Institute of Mental Health. 2021.
14. Whittal, M.L., Thordarson, D.S. and McLean, P.D., 2005. Treatment of obsessive–compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention. Behaviour research and therapy, 43(12), pp.1559-1576.
15. Whittal, M.L., Thordarson, D.S. and McLean, P.D., 2005. Treatment of obsessive–compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention. Behaviour research and therapy, 43(12), pp.1559-1576.
16. Reiff, C.M., Richman, E.E., Nemeroff, C.B., Carpenter, L.L., Widge, A.S., Rodriguez, C.I., Kalin, N.H., McDonald, W.M. and Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research, 2020. Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), pp.391-410..
17. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, 2021. Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. Focus (Am Psychiatr Publ). 19(1):95-115.
18. De Gregorio, D., Aguilar-Valles, A., Preller, K.H., Heifets, B.D., Hibicke, M., Mitchell, J. and Gobbi, G., 2021. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience, 41(5), pp.891-900.
19. Sherwood, A.M. and Prisinzano, T.E., 2018. Novel psychotherapeutics–a cautiously optimistic focus on Hallucinogens. Expert review of clinical pharmacology, 11(1), pp.1-3.
20. Jelen, L. A., & Stone, J. M. Ketamine for depression. International Review of Psychiatry,2021; 33(3): 207–228.
21. Newcomer, J.W., Farber, N.B. and Olney, J.W., 2000. NMDA receptor function, memory, and brain aging. Dialogues in clinical neuroscience, 2(3), pp.219-232.
22. Liechti, M.E., Gamma, A. and Vollenweider, F.X., 2001. Gender differences in the subjective effects of MDMA. Psychopharmacology, 154, pp.161-168.
23. Gouzoulis-Mayfrank, E., 2001. Differential actions of an entactogen compared to a stimulant and a hallucinogen in healthy humans..
24. Kargbo, R.B., 2020. Psilocybin therapeutic research: the present and future paradigm. ACS medicinal chemistry letters, 11(4), pp.399-402.
25. Al-Naggar, R.A., Alshaikhli, H. and Erlam, G., 2021. Effectiveness of Psilocybin on Depression: A Qualitative Study. Electronic Journal of General Medicine, 18(3).
26. Dyck, E., 2015. LSD: a new treatment emerging from the past. CMAJ, 187(14), pp.1079-1080.
27. NPR. Father of the Psychedelic Movement, Timothy Leary. NPR. 2020.
28. Carhart-Harris, R.L. and Goodwin, G.M., 2017. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology, 42(11), pp.2105-2113.
29. Nichols, C.D., 2022. Psychedelics as potent anti-inflammatory therapeutics. Neuropharmacology, 219, p.109232.
30. Mithoefer, M.C., Grob, C.S. and Brewerton, T.D., 2016. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry, 3(5), pp.481-488.
31. Borissova, A. and Rucker, J.J., 2024. The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych Bulletin, 48(1), pp.38-44.
32. Johnson, M.W., Griffiths, R.R., Hendricks, P.S. and Henningfield, J.E., 2018. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, pp.143-166.
33. Huang, D.S., 2020. The Efficacy of Psychedelic-Assisted Psychotherapy (Doctoral dissertation, Azusa Pacific University).
34. Nyulangone.org/news/single-dose-hallucinogenic-drug-psilocybin-relieves-anxiety-depression-patients-advanced-cancer
35. Mitchell, J.M., Ot’alora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C.R., Quevedo, S., Balliett, B. and Hamilton, S., 2023. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), pp.2473-2480.
36. Mitchell, J.M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I. and Nicholas, C., 2023. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus, 21(3), pp.315-328.
37. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S.E., Belser, A., Kalliontzi, K., Babb, J. and Su, Z., 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journalof psychopharmacology, 30(12), pp.1165-1180..
38. Garcia-Romeu, A., R. Griffiths, R. and W. Johnson, M., 2014. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews, 7(3), pp.157-164..
39. Griffiths, R.R., Johnson, M.W., Carducci, M.A., Umbricht, A., Richards, W.A., Richards, B.D., Cosimano, M.P. and Klinedinst, M.A., 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), pp.1181-1197.

Regular Issue Subscription Review Article
Volume 15
Issue 03
Received 20/09/2025
Accepted 24/10/2025
Published 26/10/2025
Publication Time 36 Days
192

Login


My IP

PlumX Metrics